USPTO's Patent Term View Oversteps Authority, Drug Co. Says

Law360, New York (May 24, 2013, 3:44 PM EDT) -- Drugmaker Exelixis Inc. has urged the Federal Circuit to overturn the patent office's current interpretation of the patent term adjustment statute, saying the office's take on the provision “oversteps” its authority and unfairly shortens the lives of patents.

The patent term adjustment statute calls for a term to be extended if the U.S. Patent and Trademark Office fails to issue a patent within three years of the date an application is filed, but companies like Exelixis have taken issue with the way the patent office calculates...
To view the full article, register now.